XXII — 22nd Century Group, Inc.

Summary of 22nd Century Group's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $4 million, a slight decrease from $4.1 million in Q2 2025.
• Total Cartons Sold: 517,000, down from 779,000 in the previous quarter.
• Gross Profit: Loss of $1.1 million, compared to a loss of $0.6 million in Q2 2025, attributed to lower sales volume and restructuring costs.
• Net Loss from Continuing Operations: Approximately $3.8 million, up from $3.3 million in Q2 2025.
• Adjusted EBITDA: Loss of $2.9 million, compared to a loss of $2.6 million in Q2 2025.
• Cash Position: $4.8 million on hand, with an additional $9.5 million received from an insurance settlement post-quarter.
• Debt: The company is now debt-free, having repaid all senior secured debt.

2. Strategic Updates and Business Highlights

• Business Model Shift: Transitioning from low-margin contract manufacturing operations to focus on higher-margin branded products, particularly Very Low Nicotine (VLN) products.
• Product Launches: Newly branded VLN and Partner VLN products are now in approximately 1,500 stores across 21 states, with plans for further expansion.
• Market Positioning: The company aims to be a leader in Tobacco Harm Reduction, advocating for the FDA's low-nicotine mandate and positioning its products as solutions to nicotine addiction.
• Technology Development: Continued focus on developing low-nicotine tobacco strains and licensing opportunities for other companies.

3. Forward Guidance and Outlook

• Breakeven Goal: The management is targeting EBITDA breakeven by Q2 2026, contingent on the successful adoption of higher-margin products and improved sales metrics.
• Growth Capital Utilization: Plans to use the available cash for operational support, expanding distribution, and initiating R&D and capital expenditures in early 2026.
• Rate of Sale Metrics: Expected to begin tracking in early 2026, which will inform future sales strategies and marketing effectiveness.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue and Volume: The decrease in revenue and total cartons sold reflects the ongoing transition away from low-margin products, which may impact short-term financial performance.
• Gross Profit Losses: Continued losses at the gross profit line highlight the challenges in shifting product mix and managing restructuring costs.
• Market Competition: The company faces competition from other technologies and products in the tobacco industry, which could impact its market share and growth potential.
• Regulatory Risks: While supportive of the FDA's low-nicotine mandate, the company operates in a highly regulated environment, which poses risks if regulations change or if competitors resist compliance.

5. Notable Q&A Insights

• Cash Utilization: Management confirmed plans to use the $14 million in cash for growth initiatives, including expanding distribution and R&D.
• Warrants and Equity: There are approximately 7 million shares outstanding, with a fully diluted basis of 23.7 million shares.
• Executive Agreements: New employment agreements for executives were established to formalize terms following the company's turnaround, with no immediate impact on SG&A.
• Breakeven Timeline: Management reiterated their commitment to achieving EBITDA breakeven by Q2 2026, despite current challenges in sales metrics.

Overall, 22nd Century Group is positioning itself for growth in the tobacco industry by focusing on VLN products and restructuring its operations, although it faces challenges in revenue generation and market competition.